Antibody data
- Antibody Data
- Antigen structure
- References [4]
- Comments [0]
- Validations [0]
Submit
Validation data
Reference
Comment
Report error
- Product number
- GTX70293 - Provider product page
- Provider
- GeneTex
- Proper citation
- GeneTex Cat#GTX70293, RRID:AB_373301
- Product name
- XRCC4 antibody
- Antibody type
- Polyclonal
- Antigen
- Recombinant protein encoding full-length XRCC4 purified from E. coli.
- Description
- Mouse polyclonal antiserum to human XRCC4
- Reactivity
- Human
- Host
- Mouse
- Isotype
- IgG
- Vial size
- 50 µl
- Concentration
- Antiserum
- Storage
- Keep as concentrated solution. Store at 4°C short term. For extended storage aliquot and store at -20°C or below. Avoid freeze-thaw cycles.
Submitted references Werner protein cooperates with the XRCC4-DNA ligase IV complex in end-processing.
Up-regulation of WRN and DNA ligase IIIalpha in chronic myeloid leukemia: consequences for the repair of DNA double-strand breaks.
Radiosensitization of MDA-MB-231 breast tumor cells by adenovirus-mediated overexpression of a fragment of the XRCC4 protein.
Adenovirus-mediated wild-type p53 radiosensitizes human tumor cells by suppressing DNA repair capacity.
Kusumoto R, Dawut L, Marchetti C, Wan Lee J, Vindigni A, Ramsden D, Bohr VA
Biochemistry 2008 Jul 15;47(28):7548-56
Biochemistry 2008 Jul 15;47(28):7548-56
Up-regulation of WRN and DNA ligase IIIalpha in chronic myeloid leukemia: consequences for the repair of DNA double-strand breaks.
Sallmyr A, Tomkinson AE, Rassool FV
Blood 2008 Aug 15;112(4):1413-23
Blood 2008 Aug 15;112(4):1413-23
Radiosensitization of MDA-MB-231 breast tumor cells by adenovirus-mediated overexpression of a fragment of the XRCC4 protein.
Jones KR, Gewirtz DA, Yannone SM, Zhou S, Schatz DG, Valerie K, Povirk LF
Molecular cancer therapeutics 2005 Oct;4(10):1541-7
Molecular cancer therapeutics 2005 Oct;4(10):1541-7
Adenovirus-mediated wild-type p53 radiosensitizes human tumor cells by suppressing DNA repair capacity.
Sah NK, Munshi A, Nishikawa T, Mukhopadhyay T, Roth JA, Meyn RE
Molecular cancer therapeutics 2003 Nov;2(11):1223-31
Molecular cancer therapeutics 2003 Nov;2(11):1223-31
No comments: Submit comment
No validations: Submit validation data